Physician profile
Danny K Lee
NPI 1851350995
$2,196.23
in general payments reported to CMS, 2019-2025
18 companies · $345 in 2025
The $345 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2020: $177 · 2021: $395 · 2022: $454 · 2023: $497 · 2024: $208 · 2025: $345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,050.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,049.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $750.57 | 2020-2025 | Clareon, Unity, Tryptyr |
| Allergan, INC. | $280.91 | 2020-2022 | |
| Biotissue Holdings INC. | $200.70 | 2023 | |
| Bausch & Lomb Americas INC. | $164.13 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Johnson & Johnson Surgical Vision, INC. | $153.00 | 2019-2025 | Tecnis Simplicity |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $113.80 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $93.76 | 2019-2022 | |
| Horizon Therapeutics Plc | $75.85 | 2022-2023 | Uplizna |
| Sun Pharmaceutical Industries INC. | $66.65 | 2022-2024 | Cequa |
| Oyster Point Pharma, INC. | $64.40 | 2022-2024 | Tyrvaya, Ryzumvi |
| Glaukos Corporation | $40.50 | 2021 | |
| Alexion Pharmaceuticals, INC. | $38.70 | 2022 | |
| Aerie Pharmaceuticals, INC. | $36.13 | 2020-2021 | |
| Boston Scientific Corporation | $30.90 | 2023 | |
| Rxsight INC | $24.05 | 2024 | Light Adjustable Lens (Lal), Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd) |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $21.51 | 2025 | |
| Dompe US, INC. | $20.49 | 2021 | |
| Ocular Therapeutix, INC. | $20.18 | 2023 | Dextenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danny Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.